Status:
COMPLETED
Post-marketing Safety Surveillance of the Injection of DanShenDuoFenSuanYan A Real World Study
Lead Sponsor:
Peking University Third Hospital
Collaborating Sponsors:
Shanghai Greenvalley Pharmaceutical Co., Ltd.
Peking University
Conditions:
Adverse Drug Reaction
Eligibility:
All Genders
Brief Summary
Magnesium Lithospermate B, the main constituent of the Injection of DanShenDuoFenSuanYan (the Injection of Depsides Salts From Salvia Miltiorrhiza), is the active ingredient of Salvia Miltiorrhiza. Th...
Detailed Description
As a traditional chinese medicine, the Injection of DanShenDuoFenSuanYan (the Injection of Depsides Salts From Salvia Miltiorrhiza) was approved by State Food and Drug Administration of China in May,2...
Eligibility Criteria
Inclusion
- Patients who use the Injection of DanShenDuoFenSuanYan in 30 hospitals in china(including the inpatient and the outpatient(only in some hospitals which can get the information)).
Exclusion
- none
Key Trial Info
Start Date :
June 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2015
Estimated Enrollment :
30180 Patients enrolled
Trial Details
Trial ID
NCT01872520
Start Date
June 1 2012
End Date
September 1 2015
Last Update
October 27 2015
Active Locations (36)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China, 233004
2
Guang'anmen Hospital affiliatied to China Academy of Chinese Medical Sciences
Beijing, Beijing Municipality, China, 100053
3
Peking university third hospital
Beijing, Beijing Municipality, China, 100191
4
The Military General Hospital of Beijing PLA
Beijing, Beijing Municipality, China, 100700